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Early-life exposures to heavy metals, pesticides,
and other neurotoxicants can lead to long-
lasting and/or delayed effects on the nervous
system (Barone et al. 2001; Thiruchelvam et al.
2002). Such effects may accelerate the natural
aging process and may be most prominent in
elderly individuals (Moser 2001). However,
early-life exposures are only one factor that may
affect functioning of the nervous system during
the geriatric period. The aging process itself has
substantial effects on the brain and peripheral
nervous system (Masoro and Snyder 2001;
Weiss 2000). In addition, exposure of elderly
individuals to neuroactive drugs or environ-
mental chemicals can alter central nervous sys-
tem (CNS) function and lead to a variety of
symptoms (Hein et al. 1990; Overstreet 2000;
Wozniak et al. 1991). Elderly individuals can
have different sensitivity to these agents than
younger adults because of pharmacokinetic
factors (chemical absorption, distribution,
metabolism, excretion) and pharmacodynamic
factors that control cellular response to the
chemical. Thus, although there has been much
focus on how early-life exposures may affect
later-life function, this inﬂuence needs to be
seen within the context of myriad other factors
that occur in elderly individuals. 
This article is a review of some of the
pharmacokinetic and pharmacodynamic
differences between younger and older adults
that may lead to altered sensitivity to chemical
exposure. The review capitalizes upon
pharmacokinetic data for therapeutic drugs in
elderly individuals to estimate geriatric/
younger adult differences in key pathways
that can affect the handling of a wide array of
xenobiotics. As shown in Figure 1, therapeu-
tic treatment of illness requires information
on both pharmacokinetics and pharmaco-
dynamics to understand interpatient variabil-
ity and how to titrate dosage for body size,
age, or genetic traits. This leads to clinical
pharmacokinetic drug trials, which when
compiled for numerous drugs can reveal
metabolism and clearance differences across
age groups (Ginsberg et al. 2002). If sufﬁcient
clinical pharmacokinetic data are available, it
may be possible to make inferences about the
handling of environmental toxicants in a par-
ticular age group such as elderly individuals.
Given that it would be unethical to pur-
posely expose a potentially sensitive population
to even trace levels of an environmental toxi-
cant, there is a lack of pharmacokinetic
(termed “toxicokinetic” when referring to toxi-
cants) data in elderly individuals. The
approach of relying on therapeutic drug stud-
ies, as described in this review, can help address
this gap. In addition a variety of exposure and
pharmacodynamic factors that can lead to
adverse drug reactions (ADRs) in elderly indi-
viduals are reviewed to help understand occur-
rences of drug-related neurologic dysfunction
in this age group.
Basic Features of Aging That
Can Affect Response to
Xenobiotics
Most of us have witnessed the relatively large
interindividual variability in the rate of aging
that exists in the human population. This
variability in the rate of aging can increase
intersubject variability in response to xenobi-
otics compared with younger adults. Although
it is clear that biologic age is more relevant
than chronologic age, it is not always easy to
obtain information showing the biologic age
of an organ system. Fortunately, this is feasible
for key pharmacokinetic factors such as
hepatic metabolism and urinary clearance
because these pathways are often determinants
of clinical pharmacokinetic studies. Such
indices are used in the titration of drug dosage
to help achieve optimal activity and minimal
side effects in elderly individuals who use
drugs with a narrow therapeutic index (Cutler
and Narang 1984; Tranchand et al. 2003).
“Normal” aging of organs and systems
leads to diminished function in many areas,
from decreased neuromuscular strength and
reaction time to losses in memory and cogni-
tion (Masoro and Snyder 2001; Weiss 2000).
These deficits can be accentuated under the
inﬂuence of physiologic or chemical stressors
due to the loss of functional reserve in aging,
leading to the manifestation of a clinical dis-
ease process or ADR. For example, defenses
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Early-life exposure to agents that modulate neurologic function can have long-lasting effects well
into the geriatric period. Many other factors can affect neurologic function and susceptibility to
neurotoxicants in elderly individuals. In this review we highlight pharmacokinetic and pharmaco-
dynamic factors that may increase geriatric susceptibility to these agents. There is a decreasing
trend in hepatic metabolizing capacity with advancing years that can affect the ability to clear thera-
peutic drugs and environmental chemicals. This factor combined with decreased renal clearance
causes prolonged retention of numerous drugs in elderly individuals. A geriatric pharmacokinetic
database was developed to analyze changes in drug clearance with advancing age. This analysis
shows that the half-life of drugs processed by hepatic cytochrome P450 enzymes or via renal elimi-
nation is typically 50–75% longer in those older than 65 than in young adults. Liver and kidney
diseases are more common in elderly individuals and can further decrease the clearance function of
these organs. Polypharmacy, the administration of numerous drugs to a single patient, is very com-
mon in elderly individuals and increases the risks for drug interaction and side effects. With
advancing age the nervous system undergoes a variety of changes, including neuronal loss, altered
neurotransmitter and receptor levels, and decreased adaptability to changes induced by xenobiotics.
These changes in the central nervous system can make elderly individuals more susceptible to
neurologic dysfunction when confronted with single pharmacologic agents, polypharmacy, or envi-
ronmental toxicants. The many factors that affect elderly responses to neuroactive agents make
environmental risk assessment for this age group a special concern and present a unique challenge.
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via http://dx.doi.org/ [Online 26 May 2005]against oxidant stress appear to decline with
age, as seen in in vitro studies in which the
basal rate of lipid peroxidation increased and
the ability to scavenge oxygen radicals
decreased with replicative age of the cell cul-
tures (Sitte et al. 2001). Increasing age has
been associated with increasing levels of lipid
peroxidation as measured by pentane exhala-
tion in human subjects (Zarling et al. 1993).
Although antioxidant levels in the frontal
lobes of the brain have been reported to
decrease in an age-related fashion (Craft et al.
2004), blood antioxidant levels and enzymes
may not be lower in older subjects unless there
is poor nutrition or active disease processes
(Vogel et al. 1997; Wouters-Wesseling et al.
2003; Zarling et al. 1993).
Another example of decreased function in
elderly individuals is impaired clearance func-
tion in both the liver and kidney, leading to a
greater potential for ADR from drug overdose
(Muhlberg and Platt 1999; Sotaniemi et al.
1997). The effects of these declines in organ
function on the pharmacokinetics of thera-
peutic drugs and toxicants are discussed in
more detail below.
Superimposed on these “normal” age-
related decreases in function are disease-related
changes in organ structure and function.
Diseases of the liver and kidney are more com-
mon and typically more advanced in elderly
individuals than in younger age groups, lead-
ing to a greater likelihood for disease-related
decreases in the pharmacokinetic processing of
drugs or environmental chemicals (Lam et al.
1997; Regev and Schiff 2001). Disease in key
clearance organs can increase intersubject vari-
ability in drug response and thus provide fur-
ther rationale for careful dose titration in
elderly individuals.
Another major factor that can affect an
elderly subject’s response to administered
drugs is the potential for drug–drug or drug–
environmental chemical interactions due to
polypharmacy. Polypharmacy is a general term
describing the use of multiple drugs, often to
address different conditions, in a single patient.
The number of drugs prescribed can be espe-
cially high when certain drugs are used to com-
bat the side effects of the primary drugs given
to treat the disease. Polypharmacy is prevalent
in elderly individuals because of the greater
number of chronic diseases that manifest with
increasing age and the greater reliance upon
pharmacologic treatment options in this age
group (Routledge et al. 2004). Polypharmacy
can stress pharmacokinetic and pharmaco-
dynamic systems that are already at a reduced
level of function due to normal aging processes
and the loss of functional reserve.
Physiologic Changes That 
Can Affect Pharmacokinetic
Function during Aging
Body composition changes with advancing
age as the percentage of muscle mass and
body water decline by as much as 25% in
women by age 70 (Masoro and Snyder 2001).
These decreases occur while body lipid is
increasing, with this compartment rising to
> 40% of body weight in elderly women and
to > 30% in elderly men (Figure 2).
These changes can be expected to cause a
larger volume of distribution and longer half-
life of lipophilic chemicals because of their
increased sequestration in fat, a tissue that is not
involved in body clearance. This has been sug-
gested for dioxin-exposed Vietnam War veter-
ans in whom sequential analysis over 15 years
showed that those with higher body lipid had
slower dioxin clearance (Michalek and Tripathi
1999). Lipid-soluble drugs have slower clear-
ance in elderly individuals, as shown for certain
benzodiazepine antianxiety drugs. For example,
diazepam’s volume of distribution and half-life
are greater in elderly individuals, which is a
function of both slower metabolic oxidation
and its high lipid solubility (Barclay 1985;
Cutler and Narang 1984; Greenblatt et al.
1983). Diazepam’s prolonged half-life has led
to its diminished use in elderly individuals, with
replacement anxiolytics such as lorazepam pre-
ferred because of more rapid pharmacokinetics.
Another factor that affects drug distribu-
tion is the decreased plasma protein binding
capacity in elderly individuals. This decrease is
15–25% and has been attributed to increased
proteinuria (loss of serum proteins to urine due
to changes in renal function) rather than to
decreased plasma protein synthesis by the liver
(Schmucker 2001). This nonspecific loss of
plasma proteins can lead to higher free drug
plasma concentration that for highly bound
drugs and environmental chemicals can lead
not only to a greater percentage available for
uptake into target organs but also to a greater
percentage available to clearance organs for
metabolism or renal elimination (Masoro and
Snyder 2001). The reduced protein binding
capacity may lead to a greater potential for
drug–drug interaction via competitive displace-
ment from the limited number of serum bind-
ing sites (Girgis and Brooks 1994).
Aging and hepatic clearance. Liver function
is generally considered to be maintained fairly
well into old age. Several liver function tests
such as serum albumin, bilirubin, cholesterol,
and alkaline phosphatase are not markedly dif-
ferent in 90-year-olds compared with young
adults (Schmucker 2001). However, liver size
and hepatic blood ﬂow are diminished 25–35%
in elderly individuals, and there is also a
decrease in bile ﬂow (LeCouteur and McLean
1998; Zeeh and Platt 2002). Histopathologic
examination of livers of aged individuals reveals
an accumulation of lipofuscin, a brown pig-
mented waste product that is formed from the
oxidation of lipids and proteins (Anantharaju
et al. 2002). This evidence suggests an increase
in hepatic lipid peroxidation and/or a decreased
capacity to remove this waste product in the
liver at advanced age. Cell culture studies
demonstrate the increased accumulation of
lipofuscin in cells undergoing oxidative stress
and with increasing replicative age, supporting
the concept that senescent cells have dimin-
ished defenses against oxidative stress (Sitte
et al. 2001).
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Figure 1. Linkage between clinical pharmacology
and environmental risk assessment.
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Figure 2. Average percent body fat versus age in
men and women: estimates from the National Health
and Nutrition Examination Survey III body mass
index data using the formulas of Lean et al. (1996).
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Figure 3. Decline in hepatic CYP function with age.
Cl, clearance. Data are mean ± SD. Adapted from
Sotaniemi et al. (1997). 
*p < 0.01. The speciﬁc content of cytochrome P450
(CYP) enzymes in the liver also diminishes dur-
ing aging. A large liver bank consisting of
226 biopsy specimens of similar histopathologic
condition was probed for total CYP content
(nmol CYP/gram liver), and antipyrine clear-
ance was measured in vivo in the same subjects
(Sotaniemi et al. 1997). Antipyrine is a non-
specific CYP substrate and thus is a general
index of hepatic CYP function. As shown in
Figure 3, when the data were broken into age
decade of donor, there is a decrease beginning
at 40–49 years of age, with further decreases in
the 60s and 70s. The maximal decline relative
to the youngest age group is 50% for hepatic
CYP content and 30% for antipyrine clearance.
This is consistent with other evidence
(Schmucker 2001) and suggests that multiple
factors such as less blood flow to the liver,
smaller liver mass, and decreased speciﬁc con-
tent of CYPs may combine in elderly individu-
als to decrease hepatic clearance of drugs.
A therapeutic drug pharmacokinetic data
set in elderly individuals was developed on the
basis of published studies to further evaluate
in vivo drug clearance function with increas-
ing age (Hattis and Russ 2003). Data for
46 drugs encompassing a variety of clearance
pathways including CYP-mediated phase I
metabolism, phase II conjugation, and renal
excretion as parent drug were included in the
database (Table 1). The database includes
results for more than 4,500 subjects, reported
as either individual or group mean data for
drug clearance, half-life, volume of distribu-
tion or area under the curve (AUC) of drug
concentration in blood × time after dosing
(Tables 2, 3). Subjects were grouped in 5-year
age increments following the reference age
group, 18–24 years of age. Most age groups
are represented by more than 100 subjects,
with the minimum number being 45 subjects
in the over-85 age group.
Analysis of changes in drug clearance
across multiple age groups and drugs was per-
formed using multiple regression techniques as
described in a previous analysis of a pediatric
pharmacokinetic data set (Ginsberg et al. 2002).
Separate regression coefﬁcients were derived for
each age group and end point [half-life, clear-
ance, AUC, volume of distribution (Vd)], with
the regression coefﬁcient representing the age
group:young adult ratio of parameter values.
Figure 4 shows geometric mean drug
clearance and half-life results across all drugs
in the database, with results expressed as the
ratio of clearance or half-life in the particular
age group compared with the reference, young
adult group. The ﬁgure shows that drug clear-
ance and half-life remain similar to the young
adult level through 60 years of age, but that
greater half-life and slower clearance are seen
in the subsequent age groups. The maximal
change is in the 80- to 84-year-old group,
with half-life increased by 60% and clearance
decreased by 50%. All age groups older
than 65 were significantly different than the
reference group except the over-85 age group,
for which the results are somewhat closer to
the reference group. However, the data for the
over-85 age group are the least robust, as they
are based upon the smallest data set.
Figure 5 provides an analysis of across-age
differences in half-life for drug groupings based
on broad categories of clearance mechanism:
CYP-mediated phase I metabolism, phase II
conjugation without prior oxidation, and renal
excretion. The results for CYP and renal elimi-
nation are consistent with the overall trend
shown in Figure 4, with signiﬁcant increases in
half-life in the over-65 age group. Once again,
the over-85 age group does not show a differ-
ence from the reference group, likely because
of the small sample size available for each path-
way. It is also possible that particularly robust
PK and PD factors in aging
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Table 1. Major routes of elimination of drugs in the geriatric pharmacokinetic database.
Table 2. Overview of the database for various parameters.
Individual  Subjects in Total no.
Parameter No. of drugs data points Data groupsa data groups (n) of subjects
AUC 17 163 21 317 480
Clearance 31 210 59 1,003 1,213
Half-life 44 359 84 1,312 1,671
Vd 26 153 51 996 1,149
Total 46 885 215 —b —b
Vd, volume distribution. 
aData sets where pooled (e.g., mean, SD) rather than individual data are available for the indicated parameter. bNot
summed to avoid double counting.
Table 3. Summary of the database by predominant modes of elimination.
Individual Subjects in Total no.
Route of elimination No. of drugs data points Data groupsa data groups (n) of subjects
All CYPs 19 389 126 2,315 2,704
Conjugation 5 122 6 60 182
Other metabolism 4 18 18 114 132
Renal and/or fecal elimination 14 278 51 892 1,170
Unclassiﬁed 4 78 14 247 325
Total 46 885 215 3,628 4,513
aData sets where pooled (e.g., mean, SD) rather than individual data are available for the indicated parameter.
Chemical Route of elimination
Amikacin Renal
Amitriptyline CYP2D6
Ampicillin Renal
Antipyrine CYP: mixed/unknown
Atracurium Esterase
Benazepril Renal
Bromazepam CYP: mixed/unknown
Bupivicaine CYP1A2
Chlorpheniramine CYP2D6
Chlorzoxazone CYP2E1
Copper Renal
Diazepam CYP2C19
Dicumarol Unclassiﬁed
Enalapril Renal
Enalaprilat Renal
Erythromycin CYP3A or 3A4
Fentanyl CYP3A or CYP3A4
Gentamicin Renal
Grepaﬂoxacin Unclassiﬁed
Ibuprofen CYP2C9
Ketanserin Unclassiﬁed
Ketoprofen Conjugation
Ketorolac Renal
Lidocaine Cyp3A or CYP3A4
Chemical Route of elimination
Lisinopril Fecal
Lithium Renal
Meperidine Esterase
Mephobarbital-r CYP2C19
Mephobarbital-s CYP: mixed/unknown
Mianserin CYP2D6
Midazolam CYP3A or CYP3A4
Nortriptyline CYP2D6
Oxazepam Conjugation
Oxytocin Other: sulfhydryl reduction
and aminopeptidase
Paracetamol Conjugation
Pethidine Esterase
Phenylbutazone Conjugation
Phenylpropanolamine Renal
Piroxicam CYP2C9
Propanolol CYP2D6
Teicoplanin Renal
Terfenadine Renal
Theophylline CYP1A2
Valproic acid Conjugation
Vancomycin Renal
Viloxazine Unclassiﬁed
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Figure 4. Change in drug clearance and half-life with
increasing age across all drugs in pharmacokinetic
database. Data points are geometric mean ± SE. individuals tend to be entered into clinical
pharmacokinetic studies at this age. Phase II
conjugation shows no evidence of decline with
advancing age.
These results indicate that the physiologic
changes in liver that occur during senescence
translate into signiﬁcantly less drug clearance in
elderly individuals older than 65. This
elderly/young adult pharmacokinetic difference
is 50–75% for drugs cleared by a variety of
CYPs or via renal excretion. The basis for the
increase in half-life for drugs cleared by renal
elimination is discussed further in the next sec-
tion. Recognition of decreased drug clearance
in elderly individuals has led to dose adjust-
ment for numerous drugs to avoid overdose.
The geriatric pharmacokinetic database
was also used to assess interindividual variabil-
ity in drug clearance in elderly age groups
compared with that in younger adults (Hattis
and Russ 2003). Figure 6 is a scatter diagram
depicting the variability in drug clearance for
individual subjects. Data are shown as the dif-
ference in clearance from that expected based
upon the overall data set regression. The ﬁgure
shows substantial interindividual variability in
each age group, but when statistically ana-
lyzed, there was no evidence for an increase in
variability in older adults. It is unclear whether
and to what degree enrollment in these various
pharmacokinetic drug trials is constrained in
terms of concurrent illnesses or drug therapy.
Such enrollment constraints would tend to
limit the degree of variability seen in the sub-
jects in these studies compared with that in
the general population, especially for older age
groups where these factors are more prevalent.
Aging and renal clearance. The aging
process has deleterious effects on renal function,
with decreases in renal weight and number of
glomeruli in subjects older than 50. In addi-
tion, the basement membrane thickens and the
number of schlerotic glomeruli increases. These
changes can occur because of normal aging but
are accelerated by the onset of disease processes
(Muhlberg and Platt 1999). Decreases in renal
blood ﬂow have been approximated at 10% per
decade beginning after the fourth decade
(Muhlberg and Platt 1999); these decreases can
lead to glomerular ischemia in elderly individu-
als. These factors combine to decrease glomeru-
lar ﬁltration rate with data from 256 geriatric
patients pooled across 17 pharmacokinetic
studies indicating a steady decline in creatinine
clearance in subjects older than 60 (Muhlberg
and Platt 1999). Subjects who had the lowest
creatinine clearance were also the ones in which
drug plasma levels attained potentially toxic lev-
els. Cisplatin and other drugs that are cleared
via renal excretion are dosed in elderly individu-
als on the basis of renal clearance function to
ensure that toxic levels do not build up in blood
(Dollery 1999; Legha 1990). Thus, titration of
drug dosage is particularly important for drugs
that are cleared by or can damage the kidneys.
For example, acyclovir-induced renal failure
and concomitant neurotoxicity are more likely
to occur in those whose creatinine clearance
rate is already somewhat diminished (Johnson
et al. 1994).
Liver and Kidney Disease 
in Elderly Individuals
The preceding discussion focused on subjects
with no overt liver or kidney disease and so
could be described as the natural course of
aging of hepatic and renal function. However,
disease-induced decrements in liver and kid-
ney clearance of xenobiotics are an important
overriding factor leading to altered pharmaco-
kinetics and possibly increased variability in
elderly individuals.
Although some organ diseases occur at
other ages as well, their prevalence and severity
are generally greater in elderly individuals
because of more time for accumulation of
damage and decreasing functional reserve
(Mahon and James 1994). The senescent liver
has reduced regenerative capacity such that
recovery is impaired in response to viral or
toxic insult or disease process (Regev and
Schiff 2001). Diseases such as alcohol-induced
cirrhosis, viral hepatitis–induced cirrhosis,
hepatocellular carcinoma, diabetic-associated
chronic liver disease, and biliary cirrhosis are
more prevalent in the elderly and are associ-
ated with replacement of functional tissue
with fibrotic or tumorous tissue or fatty
lesions (Adler et al. 2002; Amarapurkar and
Das 2002; Jansen 2002; Van Dam and Zeldis
1990). These changes can affect hepatic blood
ﬂow and the mass of metabolizing tissue avail-
able for drug clearance.
A variety of drugs can induce hepatotoxic-
ity with the possibility that reduced cellular
defenses and reserve capacity could make the
elderly individuals’ liver more susceptible to
these drugs. For example, serum transaminases
were used as an index of hepatotoxicity from
combined isoniazid/rifampin therapy in pul-
monary tuberculosis patients (Van Den Brande
et al. 1995). Before antituberculosis treatment,
serum transaminase levels were similar in a
group of 67 young patients (mean age,
38.6 years) and 64 elderly patients (mean age,
71.2 years); subjects with pre-existing hepatic
disease were eliminated from the study. During
the course of treatment, serum transaminase
levels in the young group increased approxi-
mately 2-fold, whereas a statistically greater
increase of 4- to 5-fold was seen in the elderly
group. Another study found that the incidence
and severity of hepatic side effects of antituber-
culosis therapy were high in the elderly indi-
viduals, especially those with pre-existing
hepatitis (Schaberg et al. 1996).
Sensitivity to drug-induced hepatotoxicity
is likely dependent on a number of factors,
including capability of hepatocytes to activate
and detoxify the particular drug or chemical.
Thus, one cannot generalize that elderly indi-
viduals will always be more sensitive to the
effects of hepatotoxicants. However, where
drug-induced hepatotoxicity does occur in
elderly individuals, as exempliﬁed by the anti-
tuberculosis drugs, one can expect there to be
reduced hepatic extraction of other xeno-
biotics leading to the potential for toxic drug
interactions.
Another chemical-induced hepatic effect
that may be more prevalent in elderly individu-
als is liver cancer. This may be counterintuitive
from the perspective that carcinogen exposure
at a late stage in life leaves little time for expres-
sion of the chemical-induced genetic or bio-
chemical change. However, a number of
studies have shown a greater increase in liver
tumors in response to promotional carcino-
gens (phenobarbital, peroxisome proliferators)
when dosing was initiated in aged as opposed
to young adult rats (Cattley et al. 1991;
Kraupp-Grasl et al. 1991; Ward et al. 1988).
The mechanism for this age-related vulnerabil-
ity may be that promotors act on clones of cells
that already have been transformed by an initi-
ating (typically genotoxic) carcinogen. The
Ginsberg et al.
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Figure 5. Comparison of half-life across age groups
for different clearance mechanisms. Data points
are geometric mean ± SE.
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Figure 6. Scatter plot of observed (Obs) versus
model expected (exp) log(clearance/kg bw). bw,
body weight. y= –0.0269 to 0.00050x; R2= 0.005.number of initiated clones is believed to
increase throughout the life span as a result of
cumulative exposure to initiators, thus giving
promotors a larger population of cells to act on
in elderly individuals (Cattley et al. 1991).
Renal disease is also more common in
elderly individuals. The chronic effects of
hypertension and type 2 diabetes on the renal
vasculature lead to renal diseases involving
nephroschlerosis, atherosclerosis, and athero-
embolism (Gomez et al. 1998; Mulder and
Hillen 2001; Ritz and Tarng 2001). Nephro-
pathy and reduced renal blood flow can
progress to end-stage renal disease and the need
for dialysis. Even before this point, renal disease
can lead to decreases in renal blood flow,
glomerular filtration, and tubular transport
processes (Lam et al. 1997). This can be
expected to decrease the clearance of water-
soluble drugs and drug metabolites that rely
upon glomerular ﬁltration or tubular secretion
mechanisms for entry into urine. Plasma pro-
tein binding can also be further diminished as
greater amounts of these proteins are lost from
blood into urine. Given that the effects of renal
disease on the clearance of drugs are combined
with the normal aging decrement in renal func-
tion, titration of drug dosage to renal function
as estimated by creatinine clearance is especially
important in elderly patients (Lam et al. 1997).
A variety of drugs can produce renal side
effects, such as nonsteroidal anti-inﬂammatory
agents, aminoglycoside antibiotics, ampho-
tericin B, and acyclovir. The elderly are gener-
ally more sensitive to the renal toxicity caused
by these agents because their elimination is
already compromised because of aging-related
decreased renal function, leading to greater con-
centrations in blood and kidney (Johnson et al.
1994; Muhlberg and Platt 1999). This drug-
induced worsening of renal function can lead to
interactions between these and co-administered
drugs that also rely on renal elimination.
Polypharmacy
As mentioned above, certain drugs can affect
pharmacokinetic function by producing toxic
side effects in the liver or kidney to which
elderly individuals may be more susceptible
(Girgis and Brooks 1994; Larrey 2002;
Muhlberg and Platt 1999). Additionally, a
number of pharmacokinetic mechanisms can
lead to drug–drug interaction to which elderly
individuals may be more susceptible, for exam-
ple, competition for serum protein binding
sites or for metabolic or renal elimination path-
ways (Seymour and Routledge 1998). One
example of this involves the selective serotonin
reuptake inhibitors (SSRIs), drugs that are
often prescribed to treat depression (Hemeryck
and Belpaire 2002). Fluoxetine and paroxetine
are SSRIs that are potent inhibitors of
CYP2D6 and thus can prolong the half-life of
numerous drugs. This is of concern because of
the long half-life of these SSRI agents, particu-
larly in elderly individuals, such that drug
interactions are possible for weeks after SSRI
treatment cessation (Bourin et al. 2001). For
this reason, other SSRI agents are preferred in
elderly individuals (Spina and Scordo 2002).
Although speciﬁc drugs may be risk factors
for side effects and drug interaction in elderly
individuals, the most prevalent factor for the
increase in ADR in this age group may be
polypharmacy. The elderly consume a dispro-
portionate quantity of drugs, with those older
than 65 taking, on average, two to six pre-
scribed and one to three nonprescription drugs
at any one time (Routledge et al. 2004).
Analysis of French national statistics of reported
ADRs and medication use found the expected
increase in ADRs with advancing age beyond
55 years (Begaud et al. 2002). However, the
increase was not apparent when the data were
adjusted for the number of drugs consumed
per individual in each age group (Figure 7).
This ﬁnding agrees with a careful analysis of
ADRs, prescription drug administration, age,
and other factors in a multicenter clinical study
in Italy (Carbonin et al. 1991). The doubling
of ADRs between those younger than 50 ver-
sus those older than 70 was signiﬁcantly related
to taking numerous drugs, having numerous
medical conditions, and longer hospital stays,
but there was no independent correlation with
age. It thus appears that the cumulative effect
of taking numerous drugs can challenge nor-
mal physiologic and metabolic functions at
any age, but this problem is most acute in
elderly individuals because polypharmacy is so
prevalent at this life stage.
Pharmacodynamic Aspects 
of Sensitivity to Neurotoxic
Agents in the Elderly
In addition to the pharmacokinetic and
polypharmacy factors described above, there
are numerous pharmacodynamic factors in the
CNS of elderly subjects that may affect sensi-
tivity to neuroactive agents. Changes in central
cholinergic pathways, including decreased
number of brain acetylcholine postsynaptic
receptors, have been demonstrated in rodent
models of aging and may contribute to the
progressive decline in memory and cognition
in elderly individuals (Pedigo et al. 1984).
Aged animals and humans also experience a
decline in a number of other biochemical para-
meters that are critical to central cholinergic
transmission. The activity of choline acetyl-
transferase, an enzyme in acetylcholine synthe-
sis, is diminished in older subjects. This may
be a sign that central cholinergic neurons have
diminished integrity (Overstreet 2000). The
level of brain acetylcholinesterase also decreases
during aging (Bartus et al. 1982). Thus, there
are a variety of changes during aging that could
affect sensitivity toward anticholinesterase
agents (e.g., organophosphate and carbamate
insecticides, chemical warfare agents). Some of
these changes may tend to counterbalance one
another; that is, decreased acetylcholinesterase
levels may be offset by decreased levels of acetyl-
choline synthesis or acetylcholine receptors
(Overstreet 2000). This makes it difficult to
predict whether elderly individuals will be at
higher risk to anticholinesterase agents, and
there is insufﬁcient animal data on this to draw
conclusions. However, the general diminution
of central cholinergic systems suggests decreased
functional reserve for adaptation to chemical
stresses affecting these systems. Consistent
with this is the observation of decreased neuro-
transmitter receptor plasticity in senescent rats
(Pedigo 1994). In these studies, aged rats were
unable to up- or down-regulate the numbers
of central cholinergic (muscarinic) receptors in
response to cholinergic agonists or antagonists
(Pedigo 1994). The cholinergic system decre-
ments described above are most pronounced
in those elderly with Alzheimer disease.
Another mechanism that may predispose
elderly individuals to increased sensitivity to
chemical-induced neurotoxicity is deﬁciency in
plasma and tissue esterases. Carboxylesterases
(CEs) and A-esterases (AEs) inactivate a wide
variety of organophosphate pesticides, either by
stoichiometric binding (CE) or via catalytic
hydrolysis of the activated, neurotoxic form of
the pesticide (AE). Studies in aged (24-month-
old) rats demonstrated a markedly increased
sensitivity to the acute effects of parathion but
not chlorpyrifos (Karanth and Pope 2000).
The increased sensitivity to parathion corre-
lated with a 50% reduction of plasma CE in
aged rats, whereas levels of AE were unaffected
by aging.
Changes in other CNS pathways may pre-
dispose elderly individuals to the neurotoxic
effects of drugs and environmental chemicals.
Aging involves a decline in neuron density in
the substantia nigra even in the absence of
Parkinson disease (McGeer et al. 1988; Weiss
2000), and this may be related to the increased
susceptibility of the dopaminergic system to
chemical modulation. This has been seen in
PK and PD factors in aging
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Figure 7. Age-speciﬁc rates of adverse drug reac-
tions before and after adjusting for drug consump-
tion. Modiﬁed from Begaud et al. (2002).aged rats that experienced a greater dopamine
depleting effect in the striatal region from
acute methamphetamine dosing compared
with younger rats (Bowyer et al. 1998).
Another agent affecting the central dopamin-
ergic system is 1-methyl-4-phenyl-1,2,3,6-
tetrahydropryidine (MPTP). Its acute and
residual effects on dopamine levels in the
striatum were greatest in 12-month-old mice
compared with 7-month-old (intermediate
effect) and 23-day-old mice (least effect)
(Ali et al. 1993). Additionally, the MPTP-
induced effect was rapidly reversible in the
younger animals but not in the 1-year-old age
group. Similar increases in susceptibility of
nigrostriatal neurons in aged mice has been
found for paraquat and maneb neurotoxicity
(Thiruchelvam et al. 2003).
Elderly humans and rats are more sensitive
to the excitotoxic effects of domoic and kainic
acids, structural analogs that are chemically
related to the excitatory neurotransmitter gluta-
mate (Perl et al. 1990; Teitelbaum et al. 1990;
Wozniak et al. 1991). Domoic acid contamina-
tion of mussels in Canada in 1987 led to a food
poisoning outbreak involving 107 patients,
some of whom experienced severe gastrointesti-
nal and neurologic symptoms and pathology of
the hippocampus, the main target region of the
brain. Acute and protracted neurologic effects
were more pronounced in elderly subjects,
which led to studies in young, middle-aged,
and aged rats with kainic acid (Wozniak et al.
1991). The dose response for seizures was
approximately 3 times greater in aged com-
pared with young rats. A number of changes in
excitatory and inhibitory pathways accompany
aging, including decreases in kainic acid bind-
ing in the hippocampus and increased levels of
glutamate (Masoro and Snyder 2001).
However, the mechanism for increased sensitiv-
ity to domoic and kainic acid in elderly individ-
uals has not been uncovered.
These examples point out that aging
involves pharmacodynamic changes that can
predispose to greater neurotoxic effects com-
pared with earlier life stages. Another factor
that may affect CNS function in elderly indi-
viduals is the long-term sequelae of earlier
exposure to neurotoxic agents. For example, a
study of Danish workers found that those
whose occupations involved exposure to a mix-
ture of organic solvents had a greater preva-
lence of memory loss and decreased ability to
concentrate relative to a reference group (Hein
et al. 1990). This pattern persisted into retire-
ment, where these CNS deficits and an
additional ﬁnding of increased headache mani-
fested in solvent-exposed, retired workers.
Similarly, there is evidence that occupational
exposure to heavy metals such as mercury,
manganese, aluminum, and lead can lead to
long-term decrements in neurologic function
because of the irreversible and cumulative
effects of these neurotoxicants (Hochberg et al.
1996; Payton et al. 1998; Rifat et al. 1990;
Weiss 2000).
Summary
Numerous types of exposures, either singly or
in cumulative fashion, may lead to increased
risk for neurologic deﬁcits in elderly individu-
als. Early-life exposures and workplace expo-
sures may have long-lasting effects on CNS
function that may become more signiﬁcant as
the normal aging process decreases functional
reserve. Therapeutic drugs are often a risk
factor because many are neuroactive, and sus-
ceptibility in elderly individuals is increased
because of decreased clearance or pharmaco-
dynamic factors that increase vulnerability.
The large number of drugs prescribed to an
elderly patient at a single time (polypharmacy)
and the existence of underlying pathology
of the major clearance organs or CNS can
increase the likelihood for neurotoxicity. These
factors combine to increase the possibility that
elderly individuals generally are more suscepti-
ble to the neurotoxic effects of environmental
chemicals. The extent to which this is true and
the possible size of age-related sensitivity differ-
ences has not been well studied.
Assessing risks to elderly individuals from
neurotoxicant exposure that occurs in early,
mid-, or late stages of life is challenging
because of the various factors summarized in
this article that can alter sensitivity and increase
variability in this age group. Risk assessments
can be tailored to geriatric populations by
adjusting input parameters in standard physio-
logically based pharmacokinetic (PBPK) mod-
els to account for the changes in physiology,
metabolism, and renal elimination that are
known to take place during aging (Clewell
et al. 2002). Such modeling approaches can
point out whether the internal dose of a toxi-
cant or its metabolites are likely to be elevated
in healthy geriatric subjects and in those whose
hepatic or renal function has been compro-
mised by a disease process. This type of
approach can also be useful in simulating
chemical–chemical interactions that may affect
clearance and other pharmacokinetic parame-
ters (Liao et al. 2002), an especially important
application given the numerous interactions
possible from polypharmacy in elderly individ-
uals. However, PBPK modeling of geriatric
polypharmacy will be complex and may beneﬁt
from case studies that demonstrate how this
approach can improve geriatric risk assess-
ments. Another area needing further study is
the relative sensitivity of elderly individuals to
neurotoxic agents as affected by pharmaco-
dynamic factors. The increasing emphasis
being placed on understanding the responses of
elderly individuals to drugs and environmental
toxicants should improve our ability to assess
risks for this age group in the future.
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